Clinical Trial Update: Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating dexmedetomidine for agitation in schizophrenia completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Agitation
• Schizophrenia

Drugs mentioned

• Dexmedetomidine (Dexmedetomidine)

Snippet

Sponsor: BioXcel Therapeutics Inc | Conditions: Agitation, Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2023-06-18